

Max J Gordon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9067578/publications.pdf>

Version: 2024-02-01

39
papers

621
citations

623734

14
h-index

610901

24
g-index

39
all docs

39
docs citations

39
times ranked

907
citing authors

#	ARTICLE	IF	CITATIONS
1	The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. <i>Blood Advances</i> , 2022, 6, 2701-2706.	5.2	11
2	Unusual complications in the management of <scp>chronic lymphocytic leukemia</scp>. <i>American Journal of Hematology</i> , 2022, , .	4.1	1
3	Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2041-2051.	1.3	1
4	Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. <i>British Journal of Haematology</i> , 2021, 192, 720-728.	2.5	17
5	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 46-52.	1.2	28
6	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
7	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. <i>Clinical Cancer Research</i> , 2021, 27, 4814-4824.	7.0	23
8	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	2.2	3
9	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	4.1	11
10	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
11	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072198958.	2.5	13
12	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	1.4	1
13	Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?. <i>Leukemia and Lymphoma</i> , 2021, , 1-11.	1.3	1
14	A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. <i>Leukemia Research</i> , 2020, 89, 106302.	0.8	5
15	Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1520-1532.	4.1	39
16	Pharmacologic inhibition of the ubiquitin-activating enzyme induces ER stress and apoptosis in chronic lymphocytic leukemia and ibrutinib-resistant mantle cell lymphoma cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 2946-2950.	1.3	10
17	Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 302-309.	2.3	11
18	Refractory Autoimmune Cytopenias Treated With Venetoclax. <i>HemaSphere</i> , 2019, 3, e202.	2.7	10

#	ARTICLE	IF	CITATIONS
19	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT). <i>Blood</i> , 2019, 134, 4286-4286.	1.4	3
20	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	4.1	40
21	Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. <i>Cancer</i> , 2018, 124, 3192-3200.	4.1	70
22	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	1.3	13
23	Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL. <i>Journal of Clinical Oncology</i> , 2018, 36, e19514-e19514.	1.6	1
24	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. <i>Leukemia Research</i> , 2017, 53, 39-49.	0.8	22
25	SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, 1890-1900.	3.5	27
26	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities " is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017, 10, 707-718.	2.2	8
27	Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 461-465.	1.3	23
28	Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 501-503.	2.5	22
29	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017, 178, 820-823.	2.5	4
30	Cardiac non-Hodgkin's lymphoma: clinical characteristics and trends in survival. <i>European Journal of Haematology</i> , 2016, 97, 445-452.	2.2	55
31	Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia " response to Rider <i>et al</i>. <i>British Journal of Haematology</i> , 2016, 173, 327-328.	2.5	3
32	Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics. <i>Blood</i> , 2016, 128, 1785-1785.	1.4	3
33	MIR21 is differentially expressed in the lymphoid tissue and modulated by stromal signalling in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 272-275.	2.5	3
34	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 749-754.	1.8	11
35	Targeting neddylation effectively antagonizes nuclear factor- κ B in chronic lymphocytic leukemia B-cells. <i>Leukemia and Lymphoma</i> , 2015, 56, 1566-1569.	1.3	8
36	Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 734-736.	2.5	42

#	ARTICLE	IF	CITATIONS
37	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS ONE, 2015, 10, e0143685.	2.5	32
38	Lymphoma of the Hands in a Patient With Rheumatoid Arthritis: Case Report. Journal of Hand Surgery, 2014, 39, 728-731.	1.6	3
39	An Unusual Case of Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2014, 36, e463-e464.	0.6	1